Report on the Review of Sales Transactions for Oxycodone-based Products in Atlantic Canada (Retail Pharmacies only)

July 2005

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Fact Sheet - Misuse and Abuse of Oxycodone-based Prescription Drugs

Table of Contents

• List of Appendices
• List of Figures
• List of Tables
• 1. Introduction
• 2. Limits to the Interpretation
• 3. Key Definitions for Interpretation
• 4. Demographics
  • 4.1. Regional and provincial
• 5. Volume of Transactions Distributed by Region and Province
  • 5.1. Volume of transactions, total quantity of products, average quantity per transaction and contribution ratios
    • 5.1.1. Regional and provincial
    • 5.1.2. Transactions per capita (based on 100,000 inhabitants) for Atlantic Canada
• 6. Volume of Transactions Distributed by Prime medical Specialty (Top TWO Prime medical Specialties)
  • 6.1. Volume of transactions, total quantity of products and contribution ratios
    • 6.1.1. Regional and provincial
• 7. Volume of Transactions Distributed by Product
  • 7.1. Volume of transactions by product, total quantity of products and contribution ratios
    • 7.1.1. Regional
    • 7.1.2. Provincial
  • 7.2. Volume of transactions of products by prime medical specialty
    • 7.2.1. Regional
    • 7.2.2. Provincial
• 8. Main Highlights
• 9. Conclusion

Note to Readers

The following report is based on information contained in sales transactions submitted to the Office of Controlled Substances (OCS) by Atlantic retail pharmacies. As part of this project, four levels of quality assurance were completed at the OCS to ensure completeness of information and error-free data entry. When compiling all of this information, however, the Office has not been in the position to proceed with quality control verifications on recorded data submitted by pharmacies.